Jabez Biosciences
About this raise
Jabez Biosciences is raising funds independently through Reg A+ crowdfunding. The company is pioneering the future of cancer treatment with its small-molecule therapeutics. Jabez Biosciences’ flagship drug, JBZ-001, is a DHODH inhibitor that disrupts cancer’s ability to grow and enhances the effectiveness of chemotherapy and immunotherapy. The company is led by an experienced team and aims to disrupt the oncology therapeutics market. Tamara Jovonovich and Robert Lewis founded Jabez Biosciences in 2024. The current crowdfunding round has a maximum target of $10 million. The campaign proceeds will be used for clinical trials, research and development, regulatory approvals, and market expansion.
Investment Overview
Deal Terms
- Platform
- Self Managed
- Start Date
- 12/20/2024
- Close Date
- Not Provided
$5,000
$10,000,000
$5,000
Equity - Common
Growth Stage
RegA+
$2.00
$62,284,000
Company & Team
Company
- Year Founded
- 2024
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Financials
-
Revenue
-
$0
as of Jun '24
- Monthly Burn
- $1,051
-
Runway
-
11.4 months
as of Jun '24
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $0
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 12/20/2025 | Self Managed | $62,284,000 | - | Equity - Common | Active | RegA+ |